Life Sciences Archive » June, 2013

Life Sciences - June, 2013

294 articles

• 11th Circ. Remands $10M Orders Over Medicare Scheme
• Foley Picks Up Patent Pro From Knobbe Martens
• Teva Sues Reckitt Over UK Generic-Drug Delay Tactics
• Merck, BMS Target Cipla USA Over Generic HIV Drug Sustiva
• Medtronic Hit With Shareholder Suit Over Infuse Studies
• Defending Design Defect Claims? High Court Has Your Back
• Obama's Picks For GSA, NRC Win Senate Approval
• Miss. Can't Bounce Plavix Suit To State Court, Judge Says
• Biosimilars Mark Milestone In Europe With Regulators' Nod
• Pfizer Unit, EPA Reach $2.2M Deal Over CAA Violations
• Painkiller Maker Settles With FDA Over Moldy Meds
• Woman Defends $28M Verdict In Knee Injury Row Rehearing
• Boston Scientific Puts Up $275M For Bard Cardiac Unit
• Merck Off The Hook In Fosamax Fracture Suit, Judge Rules
• Judge Won't Postpone Medicare Competitive Bid Expansion
• Bartlett's Benefits Will Extend Beyond Generic-Drug Makers
• Senate Bill Aims To Reduce Antibiotic Use In Livestock
• EU, US May Get Same Results In Pay-For-Delay Enforcement
• Smith & Nephew Patent Award Too Ambiguous, Judge Rules
• Stryker Can't Force Coverage Of $8M Knee Claims For Now
• FDA, Interpol Seize $41M In Illegal Drugs From Websites
• Ex-'Girls Next Door' Star Sued Over Weight Loss Product
• Texas Court Blocks Challenge To Medicaid Drug Pay Rules
• Ex-J&J Human Resources VP Claims Culture Of Racial Bias
• J&J Units Lodge IP Suit Over Generic Concerta
• High Court To Review Okla. Limits On Abortion Pill Use
• Deals Rumor Mill: ING, KKR, Amgen
• Aspen Makes Another $1B Growth Play With New Merck Deal
• Novartis Beats Failure-To-Warn Suit Over Zometa, Jury Rules
• Imaging3 CEO Misled Investors About 3-D Device, SEC Says
• Scientific Findings Can't Yield False Ad Claims, 2nd Circ. Says
• AbbVie Gets Humira Patent Invalidated As Obvious
• J&J Met $5M CAFA Bar In Aspirin Suits, 8th Circ. Rules
• Pfizer Can't Halt Pay-For-Delay Suit Pending Appeal
• Sandoz Fights Amgen Enbrel Patent
• Pfizer To Pay $964M In Quigley's Approved Ch. 11 Plan
• Wyeth, Cordis Stent Patents Are Invalid, Fed. Circ. Rules
• Daiichi Sankyo Loses Bid To Ship Sex Bias Suit To NJ
• Why Startups Should Focus On Patents Early On
• Medtronic Probed Over Trade Agreements Act Compliance
• Forum Clause Sank Brown Rudnick Suit Only In NJ: Judge
• FDA Sues NJ Compounder Over Mold-Contaminated Products
• FDA Details Pathways For Speedier Drug Approvals
• 11th Circ. Affirms Teva's Win In Suit Over Generic Reglan
• UK Judge Rules J&J Alzheimer Patent Invalid
• GSA, OIRA Nominees Headed For Full Senate Vote
• J&J Unit Asks 3rd Circ. To Nix Cert. In Blood Test Antitrust Row
• FDA Bars Medtronic Catheter Imports Amid 'Serious' Miscues
• Roche Settles Patent Row With Intas Over Cancer Drug Xeloda
• Hikma Sues Eagle Over $3.5M Generic-Drug Rights Deal
• BioVeris Sues Spinoffs Over $4.4M Contract Spat
• Here Comes The Sunshine Act — This Time, In Europe
• What To Know About The Common Interest Privilege
• Goodwin Procter Lands Prosecutor For Securities Team
• More BigLaw Layoffs Expected After Massive Weil Cuts
• High Court's Pass Gives Drug-Patent Safe Harbor Wide Reach
• Door Closes, Window Opens For Generic-Drug Injury Claims
• Lawyers React To High Court's Generic-Drug Liability Ruling
• FDA May Step In After High Court Shields Generic-Drug Cos.
• Deals Rumor Mill: Carrefour, Pharmstandard, Lloyds
• Possible Drug Suit Witness Can See Records Held By MLB
• High Court Vacates 2 Pay-For-Delay Rulings Post-Actavis
• FDA Restricts Cell Therapeutics Drug Trial Following Death
• EU Outlines New Rules On Releasing Drug Trial Data
• Pfizer Hits Alkem, Sandoz With Suits Over Generic Toviaz
• Judge Crushes Medtronic Bone Mill Antitrust Case
• KKR Puts Up $1.3B For Clinical Trial Provider PRA
• High Court Declines To Weigh Reach Of FCA Changes
• Supreme Court Spurns Pfizer Asbestos Liability Fight
• High Court Overturns Landmark Generic-Drug Liability Ruling
• Stiefel Labs Beats Former Exec Suit Claiming $40M Con
• High Court Isn't Keen On Class Actions, Latest Term Shows
• Brown Rudnick Sinks Malpractice Suit Over Medical Sales Row
• Judge Frowns At Insurer's Bid To Dodge Wrinkle Gel Coverage
• Plaintiffs Lawyers Still Hopeful After AmEx Ruling
• Pfizer Wins NJ Choice Of Law Ruling In HRT Mass Tort
• Myriad Ruling Vs. Biotech Patent Eligibility In Europe
• Concerns Over Drug Compounding Bills On Capitol Hill
• Vital Can't Shed Redline Energy Drink Class Action
• Lawmakers Call For Probe Of Medicare Bidding Program
• 'Black Box Warning' Counters Levaquin Claims, Judge Says
• FDA Floats Rule Tweaking Standards For Laser Products
• 'Free And Clear' Means Free And Clear
• EU Greenlights Deal For Faster US Drug Imports
• Endo To Pay $54M In Vaginal Mesh Settlement
• FDA Approves Plan B One-Step For Women Of All Ages
• Justices' AmEx Ruling Greenlights Class Action Waivers
• Surgical Centers File $15M Lawsuit Against Lap-Band Maker
• Attorneys React To High Court's Arbitration Ruling
• DOJ Sues Drugmaker Over Unapproved Misbranded Drugs
• What The High Court's AmEx Ruling Means For Corporations
• Stem Cell Co. Hits Ex-CEO With Trade Secrets Suit
• FDA Hits Drug Repackager With Mislabeling Suit
• Senate Dems Escalate Budget Battle With $1T Spending Plan
• Stryker Awarded $4.6M For Artificial Knee Litigation Coverage
• Examining The Scope Of FDA's 510(k) Recission Authority
• High-Tech Treatments Threaten Medicare Budget, Trustee Says
• Lawmakers Call For Stem Cell Research Backing At NIH
• Supreme Court Says Concepcion Covers Antitrust Cases
• Judge Boosts Royalty Rate For Syntrix's Win in Patent Row
• Sens. Say Pay-For-Delay Legislation Still Needed
• Medical Supplier Group Sues HHS To Delay Competitive Bids
• Plan B Saga Exposes FDA To Drug-Approval Suits
• Shareholder's Securities Suit Against Nautilus Tossed
• Teva Ends Class Suit With $1.3M Deal To Publicize Execs' Pay
• Judge Gives Final OK To $35M GSK Flonase Settlement
• Dynavax Accused Of Duping Investors About Hepatitis Vaccine
• Investor Sues To Block Suspected Icahn Herbalife Deal
• Justices At Odds With 3rd Circ. On Pay-For-Delay, Merck Says
• Covington Fights Doc Request In Prograf Antitrust Row
• Actavis Sues Sandoz, Hetero Over Generic Prostate Drug
• EU Fines Lundbeck $125.6M In Pay-For-Delay Probe
• Evaluating Reverse Payment Settlements After Actavis
• 5 Arguments To Look For In Pay-For-Delay Cases
• Takeda Notches Trial Win In Prevacid Patent Battle
• Reps. Label CMS Evasive, Push Bill To Delay Competitive Bids
• Novo Diabetes Drug Patent Is Obvious, Fed. Circ. Rules
• Rotech Equity Holders Lose Bid To Hire Moelis As Adviser
• Merck, Bristol-Myers Sued Over Diabetes Drugs' Cancer Risks
• Merck Investors Cut Claims In Securities Fraud MDL
• House Lawmakers Blast FDA For $1B User Fee Surplus
• Scott & Scott To Lead SAC Insider Trading Class Action
• Supplement Co. CEO Convicted Again After 9th Circ. Reversal
• Aspen Makes Play For GSK Thrombosis Drugs, Facility
• 2 Deaths Prompt FDA Probe Of Eli Lilly's Zyprexa Relprevv
• Keeping Tabs On 'Natural' Beauty And Food
• Deals Rumor Mill: Johnson Controls, Verizon, Apollo
• UK Joint Ventures: Sanctions And Corruption Risks
• Royalty Pharma Drops $8B Hostile Bid For Elan
• Pay-For-Delay Suits Get New Life Following High Court Ruling
• High Court Pay-For-Delay Ruling To Revamp Drug Patent Deals
• FTC Fought Long, Hard Battle Against Pay-For-Delay Deals
• AbbVie Targets Mylan In Latest Effort To Shield Norvir Patents
• Big Pharma's Legal Bill To Take Hit From Pay-For-Delay Ruling
• Lawyers Comment On High Court's Pay-For-Delay Decision
• Merck, Pfizer Sue Mylan Over Generic Eye Drug Application
• High Court Brings Economics Back To Pay-For-Delay Analysis
• Bayer Wants Tolling Order Nixed In $100M Sex Bias Suit
• Deals Rumor Mill: KKR, AT&T, Fiat
• Fresenius Hit With Dialysis Treatment Class Action
• J&J Inks $1B Deal To Acquire Aragon Pharmaceuticals
• Cinven Strikes $2B Deal For Rockwood's CeramTec
• DePuy Synthes Wins $16M Patent Verdict Against Globus
• Elan Vote Puts Royalty's $8B Hostile Bid In Doubt
• Pay-For-Delay Deals Can Be Illegal, Justices Rule
• NJ Victories For Novartis To Curb Zometa Pile-On Suits
• Generic Drug Labeling Claims Not Preempted By Mensing
• McKesson Dodges Warehouse Worker's Wage-Hour Action
• German Court Sides With Medtronic In Heart Valve Patent Row
• Takeda, Lupin Trim Claims In Prevacid Patent Suit
• Judge Approves $150M Flonase Antitrust Accord
• Ala. High Court To Reconsider Landmark Generic-Drug Ruling
• 8th Circ. Shields Branded Cos. For Generic-Drug Harm
• Shire Settles Intuniv Infringement Case Against Impax
• Novartis Can't Duck Elidel FCA Suit, But Kickback Claims Cut
• Elan Puts Itself Up For Sale To Avert Royalty's $8B Hostile Bid
• Deals Rumor Mill: Vodafone, Siemens, KKR
• FDA Details Clinical Trial Criteria For Combo Drugs
• Nearly All Asbestos Claimants Back New Quigley Ch. 11 Plan
• Takeaways From Largest Drug Safety Settlement
• Promega Gets Patent Claims Invalidated In DNA Analysis Row
• Attorneys React To High Court's Gene Patent Ruling
• High Court's Myriad Ruling Will Spur Novel Patent Claims
• High Court's Myriad Ruling Won't Crush Biotech Industry
• Calif. Case Gives FDA Chance To Tackle 'All-Natural' Labels
• Myriad Ruling: Some Clarity, Some Uncertainty For Biotech
• Scalia Won't Sign Off On DNA Science In Gene Ruling
• Axiom's Trade Secret, Fraud Claims Cut In Trademark Row
• Is TAR Right For Your Discovery Project?
• Suits Over 2 Stryker Hip Implants Combined Into Minn. MDL
• FDA Sued For Questioning Lupus Product's Label
• Stryker Escapes FCA Whistleblower Suit Over Pain Pumps
• FDA Pushes For Increased Medical Device Cybersecurity
• Irish Court Keeps Royalty's Hostile $8B Elan Bid Alive
• Isolated DNA Cannot Be Patented, High Court Rules
• 1st Circ. Won't Revive J&J Whistleblower's Kickback Suit
• DOJ's Compromise On Plan B Access Justified, Judge Says
• Warner Chilcott Can't Duck Consolidated Doryx Antitrust Row
• UK Moves To Regulate E-Cigarettes As Medicine
• Baxter Gets FDA Warning Letter Over Mold, Hair
• Health Clinic Can't Dodge MLB's Drug Suit
• Class Arbitration Is Back In Arbitrators' Hands
• The New Frontier Of Agreements To Negotiate
• Axiom Trademark Beef Gets New Shot In Ex-Employee Row
• Senators Push Shelanski To Curb Oversight Costs And Delays
• We're No Pyramid Scheme, Herbalife Tells Ackman
• E-Discovery Sword May Not Be Sharp Enough
• Pfizer Lands $2.15B Settlement From Teva, Sun Over Protonix
• Judge Ups Royalty Rates In $101M NuVasive Patent Verdict
• Catheter Co. Wants 'Copycat' Boston Scientific Device Banned
• Merck Drops ITC Probe Into Patented Folate Supplements
• 5th Circ. Tells Watson It Can't Review Fentanyl Jurisdiction
• Reps. Call On CMS To Delay Start Of Competitive Bidding
• Genentech Faces Arbitration Over Cancer Drug Licensing
• Royalty Goes On Offense In Ireland Over $8B Elan Bid
• Walgreens To Pay $80M To End Painkiller Sales Probe
• Takeda Diabetes Drug Caused Fatal Bladder Cancer, Suit Says
• Ex-Stiefel Employee Says Co. Bilked Him Of Full Stock Price
• Novartis Sued Over Cancer Drug's Patent Validity
• When A 3rd-Party Use Is A 'Public' Use
• Class Action Attys React To High Court's Arbitration Ruling
• Fed. Circ. Junks Merck's Nasonex Patent Suit Against Apotex
• High Court Ruling Pushes Cos. To Tighten Arbitration Deals
• 5 Tips For An Airtight Approach To ACA Sunshine Rule
• White House Drops Effort To Restrict OTC Morning-After Pills
• Baxter Bosses Sued Over $588M Pump Recall, Plasma Prices
• DOL Tip-Pooling Loss May Spur More Agency Rule Challenges
• Elan Drops Suit After Royalty Opens Up On $8B Hostile Bid
• FDA Balks At Renal Cancer Drug From Aveo, Astellas
• Ex-Bristol-Myers Squibb Exec Admits To Insider Trading
• Shire Says Patent Deals Didn't Block Generic Adderall
• Sens. Want Quick Vote On Drug Compounder Oversight Bill
• High Court Urged To Ban Injunctions On Patent Infringement
• SEC Probing Cardiovascular Systems Over PE Firm's Trading
• Justices Defer To Arbitrator On Oxford Class Arbitration
• GSK Thalidomide Suit To Stay In Fed. Court: 3rd Circ.
• Flector FCA Suit Short On Evidence, Pfizer Unit Says
• AstraZeneca Inks Back-Loaded $1.15B Deal For US Drugmaker
• FCPA Powerhouse: WilmerHale
• Dear Mobile Medical App Developers ...
• Do-Or-Die For Four M&A Deals This Week
• Eisai Destroyed Evidence In Antitrust Case, Sanofi Says
• K-V Judge Signs Off On Investors' $275M Plan
• No Proof Patterson Atty Shared Trade Secrets, J&J Says
• Everett Hits Rival Acella With 2 Prenatal Patent Suits
• Stiefel Crying Wolf Over Worker's $2M Win, 11th Circ. Told
• Ex-InterMune Official Settles SEC Insider Trading Suit
• Claims Trimmed In Abbott Baby Formula Contamination Suit
• Google Threatened With Subpoena Over Painkiller Searches
• MDL Panel Combines Suboxone Antitrust Cases In Pa.
• Deals Rumor Mill: Fiat, Icahn, HSBC
• Royalty Pharma Makes Sweetened $8B Bid For Elan
• Fresenius Targets Actavis With IP Suit Over Diprivan
• FCPA Powerhouse: Willkie Farr
• When In Doubt, Write Your Doctor A Letter
• AbbVie Hits Dr. Reddy's With IP Suit Over Generic Zemplar
• Chemistry Journal Defamed Cardiac Testing Co., Suit Says
• TCPA Junk Fax Suit Against J&J Unit Wins 2nd Chance
• Bard Limits Plaintiffs' Expert Testimony In Vaginal Mesh MDL
• FCPA Powerhouse: Venable LLP
• FDA Can't Regulate Lab Tests As Devices, Group Says
• FDA Panel Backs Looser Limits On GSK's Avandia
• Teva Settles With BMS, Merck Over HIV Drug Generic Plans
• Royalty In 'Wait-And-See' Mode With $6.3B Elan Tender Offer
• Faegre Baker Daniels To Open New Office In Silicon Valley
• West-Ward Pharma Drops False Ad Suit Against Rivals
• Infringement Liability May Exist For Foreign Manufacturers
• 1st Circ. Ruling Highlights Split On FCA First-To-File Bar
• Fla. Pharmacy Says Walgreens Lifted Its 'Teamcare' Mark
• Mediators, Expand Your Tool Kit In Complex Litigation
• Texas Court Urged To Toss $4M Fen-Phen Referral Fee Award
• 9th Circ. Revives ERISA Action Over Amgen Stock Drop
• 2nd Circ. Rejects Delay Of OTC Morning-After Pill
• Biosimilars Dodge State Roadblocks, But Big Hurdles Remain
• Abbott Can't Kick Investor Suit Over Depakote Marketing
• Ex-SAC Manager Gets Date For Insider Trading Trial
• Review Of GSK's Avandia Trial Flawed, FDA Official Says
• Handa's Generic Dexilant Infringes Takeda IP, Judge Hears
• Elan Withdraws Irish Bid To Block Royalty Takeover
• IRS Withholding $125M Owed In Abbott Case, Va. AG Says
• Momenta Urges Justices To Clarify Drug Safe Harbor Rule
• Ex-Becton Engineer Accused Of Lifting Trade Secrets
• Braintree Beats Colon-Cleanser Patent Invalidity Claims
• FCPA Powerhouse: Reed Smith
• Merck Sues Watson Labs To Block Generic Contraceptive
• New Opportunities For VC-Backed Life Sciences Cos.
• Elan Wins Injunctions, But Hostile Bidder Gets ISS Support
• Public Health Workers Urge FDA Action On Antibiotics
• Illumina Trashes Life Tech's Bid To Upset DNA Patent Win
• Merck Presses Fed. Circ. To Reopen Nasonex Battle
• J&J Issues Global Recall Of Cilest Birth Control Pills
• Purchasers Seek Covington Docs In Prograf Antitrust Row
• Rembrandt Asks Fed. Circ. To Revive J&J Contact Lens Row
• Fetal Viability Rule Doesn't Nix Paxil Suit, Pa. Court Told
• Mylan Must Produce Blood Pressure Meds In Apotex IP Row
• Sebelius Likens ACA Fundraising To Previous GOP Efforts
• After FDA Review, GSK Could Earn Reprieve On Avandia
• Not-So-Sunny Requirements Of CMS' Sunshine Act
• Bristol-Myers Copay Subsidies Not Bribes, Judge Finds
• Takeda, Eli Lilly Want Ark. Taxpayer's Actos Suit Nixed
• Vitamin C Co. Pushes To Ax $153M Antitrust Award
• AstraZeneca Unit's Ch. 11 Case Gets The Ax
• Omthera Investor Challenges $443M AstraZeneca Buyout
• Shire Says Patent Settlements Didn't Delay Generic Adderall
• FDA Clarifies Modification Process For Blood Products
• Fed. Circ. Affirms AGA Patent Win In Heart Device IP Row
• Justices Pass On 2nd Circ. Fosamax Jaw-Injury Ruling
• Axiom Wins Infringement Ruling In Device Trademark Row
• Maxygen Says It Will Liquidate, Pay Off Shareholders
• FCPA Powerhouse: Gibson Dunn
• Pfizer, GSK Price-Fixing Suit Won't Get High Court Review
• FCA First-To-File Rule Sinks Kickback Suit, 1st Circ. Says
• IOM Report — Worth Its Salt For Future Health Policy
• Don't Use 'Could You Patent The Sun?' Against Myriad